Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went UnaddressedGlobeNewsWire • 03/05/26
Levi & Korsinsky Investigates GRAIL, Inc. (GRAL) Over Possible Securities FraudNewsfile Corp • 03/02/26
Lost Money on GRAIL, Inc. (GRAL)? Possible Fraud - Contact Levi & Korsinsky TodayNewsfile Corp • 02/24/26
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law FirmPRNewsWire • 02/24/26
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%The Motley Fool • 02/23/26
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collectionFox Business • 02/23/26
This once-hot cancer-detection company's stock got cut in half after a failed trialMarket Watch • 02/20/26
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law FirmGlobeNewsWire • 02/20/26
Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.Barrons • 02/20/26
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesBusiness Wire • 02/20/26
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection RatePRNewsWire • 02/19/26
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection TestZacks Investment Research • 01/30/26
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection TestPRNewsWire • 01/30/26